Pramiracetam


Diisopropylaminoethyl 2-oxopyrrolidineacetamide racetam nootropic with selective high-affinity choline uptake potentiation

A lipophilic piracetam analog developed at Parke-Davis as a cognition-enhancing agent, distinguished from the parent racetam by potent modulation of hippocampal high-affinity choline uptake and marketed in select European jurisdictions for age-related cognitive impairment and attention deficits.

Abstract

Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39 g/mol) is a second-generation nootropic of the racetam class, synthesized at Parke-Davis in the late 1970s as a structural analog of piracetam. Pramiracetam was advanced through preclinical and clinical development at Parke-Davis (then a division of Warner-Lambert, subsequently acquired by Pfizer) with the development code CI-879. The compound was licensed to Menarini for European development and was marketed under the trade names Pramistar, Neupramir, and Remen in Italy, Belgium, and several Eastern European jurisdictions for the treatment of memory and attention deficits in aging populations with neurodegenerative and vascular dementias. The Italian marketing authorization under Menarini was maintained until 2020, when it was voluntarily withdrawn by the manufacturer. The principal pharmacological mechanism of pramiracetam, characterized in the Pugsley et al. (1983) and subsequent studies, is selective enhancement of high-affinity choline uptake (HACU) in hippocampal and cortical cholinergic nerve terminals [1]. HACU is the rate-limiting step in acetylcholine biosynthesis; pramiracetam increases the velocity of choline transport into presynaptic cholinergic neurons without altering monoamine neurotransmitter concentrations, receptor binding profiles at dopaminergic, serotonergic, adrenergic, or histaminergic sites, or monoamine oxidase activity. The selectivity of the HACU mechanism distinguishes pramiracetam from piracetam, which acts predominantly through AMPA receptor positive allosteric modulation and membrane fluidity enhancement. Additional preclinical findings include increased nitric oxide synthase activity in rat cerebral cortex following systemic administration [2] and normalization of age-related electroencephalographic abnormalities in aged Fischer-344 rats [3]. The compound does not exhibit direct cholinesterase inhibition, muscarinic or nicotinic receptor agonism, or GABAergic activity at pharmacologically relevant concentrations. The absence of significant cytochrome P450 involvement reduces drug-drug interaction liability relative to hepatically metabolized nootropic and cholinergic agents. Effect sizes across these studies are consistently small to moderate, and the compound has not produced a positive Phase 3 registration-quality readout in Alzheimer disease. Pramiracetam is not approved by the United States Food and Drug Administration and is classified as an unapproved new drug in the United States. It is available as a research-grade chemical from multiple suppliers. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph